Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

被引：18

作者：

Boudewijns, Steve ^{[1
,2
]}

Koornstra, Rutger H. T. ^{[1
]}

Westdorp, Harm ^{[1
,2
]}

Schreibelt, Gerty ^{[2
]}

van den Eertwegh, Alfons J. M. ^{[3
]}

Foppen, Marnix H. Geukes ^{[4
]}

Haanen, John B. ^{[4
]}

de Vries, I. Jolanda M. ^{[1
,2
]}

Figdor, Carl G. ^{[2
]}

Bol, Kalijn F. ^{[1
,2
]}

Gerritsen, Winald R. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Geert Grootepl,Zuid 10, NL-6525 GA Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Tumor Immunol, Nijmegen, Netherlands

[3] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands

[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

来源：

ONCOIMMUNOLOGY | 2016年 / 5卷 / 08期

关键词：

Dendritic cell vaccination; immunotherapy; ipilimumab; melanoma; PRETREATED ADVANCED MELANOMA; LONG-TERM SURVIVAL; PHASE-II; T-CELLS; TUMOR MICROENVIRONMENT; ANTITUMOR RESPONSES; CANCER VACCINES; STAGE-III; COMBINATION; IMMUNOTHERAPY;

D O I：

10.1080/2162402X.2016.1201625

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2-10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.

引用

页数：9

共 43 条

[1] Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination [J].

Aarntzen, Erik H. J. G. ;

De Vries, I. Jolanda M. ;

Lesterhuis, W. Joost ;

Schuurhuis, Danita ;

Jacobs, Joannes F. M. ;

Bol, Kalijn ;

Schreibelt, Gerty ;

Mus, Roel ;

De Wilt, Johannes H. W. ;

Haanen, John B. A. G. ;

Schadendorf, Dirk ;

Croockewit, Alexandra ;

Blokx, Willeke A. M. ;

Van Rossum, Michelle M. ;

Kwok, William W. ;

Adema, Gosse J. ;

Punt, Cornelis J. A. ;

Figdor, Carl G. .

CANCER RESEARCH, 2013, 73 (01) :19-29

[2] Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma [J].

Aarntzen, Erik H. J. G. ;

Bol, Kalijn ;

Schreibelt, Gerty ;

Jacobs, Joannes F. M. ;

Lesterhuis, W. Joost ;

Van Rossum, Michelle M. ;

Adema, Gosse J. ;

Figdor, Carl G. ;

Punt, Cornelis J. A. ;

De Vries, I. Jolanda M. .

CANCER RESEARCH, 2012, 72 (23) :6102-6110

[3] Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients [J].

Aarntzen, Erik H. J. G. ;

Schreibelt, Gerty ;

Bol, Kalijn ;

Lesterhuis, W. Joost ;

Croockewit, Alexandra J. ;

de Wilt, Johannes H. W. ;

van Rossum, Michelle M. ;

Blokx, Willeke A. M. ;

Jacobs, Joannes F. M. ;

Duiveman-de Boer, Tjitske ;

Schuurhuis, Danita H. ;

Mus, Roel ;

Thielemans, Kris ;

de Vries, I. Jolanda M. ;

Figdor, Carl G. ;

Punt, Cornelis J. A. ;

Adema, Gosse J. .

CLINICAL CANCER RESEARCH, 2012, 18 (19) :5460-5470

[4] Clinical use of dendritic cells for cancer therapy [J].

Anguille, Sebastien ;

Smits, Evelien L. ;

Lion, Eva ;

van Tendeloo, Viggo F. ;

Berneman, Zwi N. .

LANCET ONCOLOGY, 2014, 15 (07) :E257-E267

[5] Combination of Alphavirus Replicon Particle-Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates [J].

Avogadri, Francesca ;

Zappasodi, Roberta ;

Yang, Arvin ;

Budhu, Sadna ;

Malandro, Nicole ;

Hirschhorn-Cymerman, Daniel ;

Tiwari, Shakuntala ;

Maughan, Maureen F. ;

Olmsted, Robert ;

Wolchok, Jedd D. ;

Merghoub, Taha .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (05) :448-458

[6] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[7] Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma [J].

Bedikian, Agop Y. ;

Johnson, Marcella M. ;

Warneke, Carla L. ;

Papadopoulos, Nicholas E. ;

Kim, Kevin ;

Hwu, Wen-Jen ;

Mclntyre, Susan ;

Hwu, Patrick .

CANCER INVESTIGATION, 2008, 26 (06) :624-633

[8] Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination [J].

Bol, Kalijn F. ;

Aarntzen, Erik H. J. G. ;

in 't Hout, Florentien E. M. ;

Schreibelt, Gerty ;

Creemers, Jeroen H. A. ;

Lesterhuis, W. Joost ;

Gerritsen, Winald R. ;

Grunhagen, Dirk J. ;

Verhoef, Cornelis ;

Punt, Cornelis J. A. ;

Bonenkamp, Johannes J. ;

de Wilt, Johannes H. W. ;

Figdor, Carl G. ;

de Vries, I. Jolanda M. .

ONCOIMMUNOLOGY, 2016, 5 (01)

[9] Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity [J].

Bol, Kalijn F. ;

Aarntzen, Erik H. J. G. ;

Pots, Jeanette M. ;

Nordkamp, Michel A. M. Olde ;

van de Rakt, Mandy W. M. M. ;

Scharenborg, Nicole M. ;

de Boer, Annemiek J. ;

van Oorschot, Tom G. M. ;

Croockewit, Sandra A. J. ;

Blokx, Willeke A. M. ;

Oyen, Wim J. G. ;

Boerman, Otto C. ;

Mus, Roel D. M. ;

van Rossum, Michelle M. ;

van der Graaf, Chantal A. A. ;

Punt, Cornelis J. A. ;

Adema, Gosse J. ;

Figdor, Carl G. ;

de Vries, I. Jolanda M. ;

Schreibelt, Gerty .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (03) :327-339

[10] Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients [J].

Bol, Kalijn F. ;

Figdor, Carl G. ;

Aarntzen, Erik H. J. G. ;

Welzen, Marieke E. B. ;

van Rossum, Michelle M. ;

Blokx, Willeke A. M. ;

van de Rakt, Mandy W. M. M. ;

Scharenborg, Nicole M. ;

de Boer, Annemiek J. ;

Pots, Jeanette M. ;

Nordkamp, Michel A. M. Olde ;

van Oorschot, Tom G. M. ;

Mus, Roel D. M. ;

Croockewit, Sandra A. J. ;

Jacobs, Joannes F. M. ;

Schuler, Gerold ;

Neyns, Bart ;

Austyn, Jonathan M. ;

Punt, Cornelis J. A. ;

Schreibelt, Gerty ;

de Vries, I. Jolanda M. .

ONCOIMMUNOLOGY, 2015, 4 (08)

← 1 2 3 4 5 →